• Contact
  • OmniSeq Connect Portal
OmniSeq
  • Clinical Testing
    • OmniSeq INSIGHT
    • Order Test
    • Specimen Requirements
  • BioPharma Services
  • Publications
  • Patient Support
    • CARES Program
    • Frequently Asked Questions
  • About
    • About
    • Leadership
    • Careers
    • News
    • Forms
    • Contact
Select Page

Inflammation Signature May Predict Checkpoint Inhibitor Response in Gastroesophageal Cancer, Study Finds

by Christina Black | Jul 22, 2021 | News

Labcorp and OnmiSeq Launch Insight, Next-Generation Sequencing Platform to Advance Precision Oncology

by Christina Black | Jun 10, 2021 | News

OmniSeq Receives New York State Approval for Cancer Genomic, Immune Profiling Test

by Christina Black | Apr 27, 2021 | News

OmniSeq Offers Differentiating Platform to Clinically Detect Rare Genetic Alterations to Identify Patients Eligible for New, Targeted Therapy for Lung and Thyroid Cancer

by Christina Black | Jun 30, 2020 | News

NGS Test Uses RNA-Sequencing to Detect RET Fusions and DNA-Sequencing to Detect RET Mutations BUFFALO, N.Y., June 29, 2020 /PRNewswire/ — OmniSeq®, an innovator in next generation sequencing (NGS) in oncology, today announced the benefits of its OmniSeq Advance®...

OmniSeq Appoints Chief Medical Officer, Roger D. Klein, M.D., J.D., FCAP

by Christina Black | Apr 7, 2020 | News

FOR IMMEDIATE RELEASE MEDIA CONTACT: Sawyer Lipari Lambert & Co. 313.309.9551 slipari@lambert.com OmniSeq Appoints Chief Medical Officer, Roger D. Klein, M.D., J.D., FCAP Leading molecular diagnostic company’s new hire to support oncology product development...
« Older Entries

Follow Us on Twitter

OmniSeqFollow

Avatar
AvatarOmniSeq@OmniSeq·
6h

https://tinyurl.com/c2pjh9zm
In case you missed it, you can now view the ASCO 2021 by Dr. Robert Phillips, “Reimagining Precision Medicine Throughout a Patient’s Journey” highlighting @OmniSeq INSIGHT.
@Labcorp @LabcorpDrugDev
#PrecisionMedicine

Reply on Twitter 1419708503682437123Retweet on Twitter 1419708503682437123Like on Twitter 14197085036824371232Twitter 1419708503682437123
AvatarOmniSeq@OmniSeq·
19 Jul

Learn how @OmniSeq utilizes tumor immunogenic profiles to describe immune tumor microenvironments in multiple tumor types and to help predict clinical benefit from immune checkpoint inhibitors (ICIs) https://biomarkerres.biomedcentral.com/articles/10.1186/s40364-021-00308-6
#oncology
#precisionmedicine

Reply on Twitter 1417130259913314310Retweet on Twitter 1417130259913314310Like on Twitter 14171302599133143104Twitter 1417130259913314310
Retweet on TwitterOmniSeq Retweeted
AvatarSarabjot Pabla@PablaSabi·
18 Jul

Our work on integrating tumor inflammation and proliferation biomarkers in solid tumors is out. Read more here: https://biomarkerres.biomedcentral.com/articles/10.1186/s40364-021-00308-6
@OmniSeq #cancerresearch #immunotherapy #immunooncology #oncology #oncologyresearch #oncologyclinicalresearch

Reply on Twitter 1416848609832751107Retweet on Twitter 14168486098327511073Like on Twitter 14168486098327511077Twitter 1416848609832751107
Retweet on TwitterOmniSeq Retweeted
AvatarRoswell Park@RoswellPark·
2 Jul

Sarbajit Mukherjee, MD, MS, shared his findings on the link between inflammation, immunotherapy and outcomes, while his mentee, Lei Deng, MD, shared his findings on the patients most likely to benefit from chemo after surgery.

Reply on Twitter 1410991725355601922Retweet on Twitter 14109917253556019223Like on Twitter 14109917253556019226Twitter 1410991725355601922
AvatarOmniSeq@OmniSeq·
23 Jun

In case you you missed it!!! Laboratory Corporation of America and OmniSeq have launched the OmniSeq INSIGHT genomic and immune profiling test.
https://tinyurl.com/nmm8a4rr

@GenomeWeb
@Labcorp
#precisionmedicine
#oncology

Reply on Twitter 1407818171168395268Retweet on Twitter 1407818171168395268Like on Twitter 14078181711683952685Twitter 1407818171168395268
Load More...

  • Facebook
  • Twitter
©2021 OmniSeq Corporation | Privacy Practices and Terms of Use. Regulatory   .